clinical trial · NCT05165433
Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)
Akamis Bio·phase1·completed·n = 14
Epithelial TumorMetastatic CancerNG-350A plus Pembrolizumab
brief summary
This is a phase 1a/1b, multicentre, open-label, non-randomized study of NG-350A in combination with pembrolizumab in patients with metastatic or advanced epithelial tumours.
started
Apr 13, 2022
primary completion
Aug 29, 2025
completion
Sep 26, 2025
last updated
Dec 16, 2025
detailed description
Phase 1a will investigate NG-350A administration by intravenous (IV) infusion in combination with fixed-dose pembrolizumab in patients with metastatic or advanced tumours.
Phase 1b will further investigate the efficacy and safety of the selected dose regimen in up to three of the tumour types evaluated in Phase 1a.
official title
A Multicentre, Open-label, Non-randomized, Phase 1a/1b Study of NG-350A, a Tumour-selective Anti-CD40-expressing Adenoviral Vector, in Combination With Pembrolizumab in Patients With Metastatic or Advanced Epithelial Tumours
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol